European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Visa to Move European Headquarters to London’s Canary Wharf 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Genexine, the South Korean biotechnology company, is said to have made a deal with PT Kalbe Farma, an Indonesian pharmaceutical firm. The contract is about the supply of 10 million doses of the COVID-19 vaccine that it is currently developing.
The vaccine supply deal
The information about Genexine’s agreement with the Indonesian pharma was reported on Tuesday, April 27. While the Korean company is not done yet with the clinical tests for its vaccine brand, PT Kalbe Farma is confident enough for its effectiveness since it already placed an order.
But then again, The Korea Herald pointed out that the deal is not fully done yet. This is because the sale will only be possible if the government of Indonesia will approve the Genexine vaccine for emergency use.
Once everything is ironed out, the purchase of 10 million doses of coronavirus vaccine that Genexine named GX-19NA will be finalized. At this point, it was mentioned that the shot is still in the second phase of the clinical trial. A third one is expected to follow soon.
After the purchase, it was reported that Genexine will be receiving royalties based on sales of the vaccine through PT Kalbe Farma.
Phase 3 of the clinical trial
Genexine and PT Kalbe Farma have submitted applications for the second and third stages of the trials to the Indonesian Food and Drug Authority. The latter will be funding the cost of the clinical studies and since this is the arrangement, Genexine will not be given a downpayment for the order of 10 million doses, Korea Bio Med reported.
They also forwarded an application for an investigational new drug (IND) to the Indonesia National Agency of Drug and Food Control. It has been almost a month since the submission and they are waiting for approval.
"Indonesia has faith in the safety and efficacy of GX-19N, promised to conduct the joint clinical trials, and pre-ordered the vaccine candidate," Woo Jung Won, Genexine’s chief executive officer, said. "We will provide a safer Covid-19 vaccine for Indonesia and Korea through the successful development of GX-19N."
Meanwhile, no serious adverse effects were noted in the clinical trials that have been done so far.
